The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
The region stands out for its prowess in invention and innovation, but competing markets have mastered telling their stories, according to speakers at IBJ’s Life Sciences Power Breakfast.
Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley Children’s Health, has been working on a treatment for a neurodegenerative condition called Friedreich’s ataxia for decades.
The focus of the agreement is to meet the evolving needs of Indiana’s orthopedic sector, which represents one-third of the industry’s global workforce.
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
The company has a goal to build a massive bank of bone marrow from deceased organ donors to treat patients with blood cancers and improve organ transplantations.
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
The Indianapolis-based pharmaceutical giant and the state’s Office of Energy Development signed a nonbinding letter of intent to explore the potential deployment of small modular reactors.
Clark participated in a health care-related panel sponsored by Eli Lilly and Co. at the Final Four Fan Fest at the Indiana Convention Center on Friday.
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
This weekend’s event will feature nearly 20 interactive fan areas, often called activations, from more than a dozen of the NCAA’s business partners and sponsors.
The Indianapolis-based drugmaker is challenging a $183.7 million judgment in a case brought by a pharmacist who alleged Lilly made false claims about rebates to the federal Medicaid program.
The series will provide a forum for business and community leaders, local elected officials, academic leaders, entrepreneurs and investors to come together for candid discussions about the opportunities to fuel Indiana’s economic growth.
